# AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger

- URL: https://talkfuse.com/story/astrazeneca-should-stick-to-its-winning-formula-it-doesnt-need-a-400bn-us-mega-merger/
- Published: 2026-08-03T17:22:28+00:00
- Updated: 2026-08-03T17:49:25+00:00
- Original publisher: The Guardian (publisher lean: Left)
- Original article: https://www.theguardian.com/business/2026/aug/03/astrazeneca-should-stick-to-winning-formula-doesnt-need-400bn-us-mega-merger
- Topics: Americas, Art, Business, Companies, Culture, Health, Markets, Medicine, World

## Key points

- AstraZeneca in merger talks with Bristol Myers Squibb worth $400bn
- Shares fell 8.9% on the news; deal seen as risky and unnecessary
- Columnist says AZ's existing licensing-led strategy is already working well

## Summary

Guardian columnist Nils Pratley argues AstraZeneca does not need a $400bn (£300bn) mega-merger with US firm Bristol Myers Squibb, warning that pursuing one would risk undermining chief executive Sir Pascal Soriot's otherwise successful tenure. Reports of the potential tie-up sent AstraZeneca shares down 8.9%, reflecting investor unease about a deal that would saddle the Anglo-Swedish drugmaker with substantial debt despite AZ already having a strong, self-sufficient growth strategy.

Soriot has built AZ's success on developing its own drugs alongside smart licensing and partnerships, notably in China, rather than large-scale consolidation, and analysts including Jefferies note the company has no need for such "financial engineering". A merger would also mean inheriting BMS's looming patent cliff, with sales of its blockbuster Opdivo cancer drug expected to fall sharply before 2030, while a combined oncology giant would likely face a long and distracting US regulatory approval process. Soriot recently reaffirmed confidence in AZ's 2030 target of $80bn in annual revenue, despite one late-stage drug trial failure, citing 20 major drug results due over the next 18 months as reason to stick with the current strategy.

---
Summarised by TalkFuse (https://talkfuse.com/). Quote the original publisher for the reporting and link this page for the summary and discussion.
